Monograph
B06AC02 - Icatibant |
Propably not porphyrinogenic |
PNP |
Rationale
Icatibant is not metabolized by CYP enzymes.
Nausea is a common side effect that can be potentially porphyrinogenic through reduction in caloric intake.
Therapeutic characteristics
Icatibant is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).
A common side effect that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack is nausea. Other common side effects are dizziness and headache.
Metabolism and pharmacokinetics
Icatibant is metabolized by proteolytic enzymes. Elimination half-life is 1-2 hours.
In vitro studies have shown that icatibant is not metabolized by oxidative metabolic pathways and it is not an inhibitor of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4, or and inducer of CYP1A2 and CYP3A4 (SPC).
References
| # |
Citation details |
PMID |
|---|
| * | Summary of Product Characteristics |
| 1. |
Norwegian medicines agency. Summary of Product Characteristics (SPC). Icatibant.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
